Table 2.
DCR of patients with osteosarcoma using anlotinib as first-line therapy, second-line therapy, or beyond second-line therapy.
| Treatment line | DCR | ||
|---|---|---|---|
| Anlotinib | Anlotinib plus chemotherapy | Total | |
| First line | 0 (0/0) | 0 (0/2) | 0 (0/2) | 
| Second line | 50 (2/4) | 75 (3/4) | 63 (5/8) | 
| Beyond second line | 67 (2/3) | 0 (0/0) | 67 (2/3) | 
| Total | 57 (4/7) | 50 (3/6) | 54 (7/13) |